Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.52 -0.28%

-$0.04 today

Market cap
$102.61M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.17M

Average 0.27M

IMUX Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Immunic, Inc.NASDAQ: IMUX

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow declines year over year

Q1 FY2026 investing cash flow of $2K (cash outflow) fell 95.7% year over year, behind the -58.6% change in trailing-twelve-month investing cash flow. Sequentially, it fell 81.8% from the prior quarter. Over 3 fiscal years it compounded at -74.5% a year.

Context

  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -95.7% toward the trailing-twelve-month pace of -58.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2K-81.8% QoQ
Last fiscal yearDec 2025
-$161K-39.0% YoY
LTMMar 2026
-$116K-58.6% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-95.7%——
1 year-39.0%——
3-year CAGR-74.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(161K) USD
Year-over-year change
+39.0%

Investing Cash Flow vs competitors

How IMUX compares with its peers on the latest reported figures

  • IMUX's LTM Mar 2026 investing cash flow of $116K is the smallest of the 9 companies compared; the peer median is $13.43M.
  • Its year-over-year change of -58.6% is the 7th highest of 9, against a peer median of +154.3%.
  • Over three fiscal years its annual growth of -74.5% compares with a peer median of -27.6%.
IMUX Competitors Peer median
Investing Cash Flow for IMUX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$198.73M -449.5%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026$95.77M +227.3%—1048.3%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$62.28M +11.4%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$60.01M +256.3%——
ACETAdicet Bio, Inc.LTM Mar 2026$24.13M +119.8%——
VXRTVaxart, Inc.LTM Mar 2026$2.72M +188.8%—1.1%
BMEABiomea Fusion, Inc.LTM Mar 2026$550K +268.2%——
CBUSCibus, Inc.LTM Mar 2026$359K -58.8%-27.6%8.4%
IMUXImmunic, Inc.LTM Mar 2026$116K -58.6%-74.5%—
Peer median (excluding IMUX) $13.43M+154.3%-27.6%8.4%

Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Depreciation & Amortization85K77K111K134K168K
Deferred Income Tax4.33M0000
Stock-Based Compensation5.95M7.93M7.1M8.53M8.86M
Change in Working Capital(9.28M)9.53M15.05M564K1.84M
Accounts Receivables00000
Inventory00000
Accounts Payables176K799K817K3.15M1.24M
Other Working Capital(9.46M)8.73M14.23M(2.58M)601K
Other Non-Cash Items8.63M37.73M523K6.52M497K
Operating Cash Flow(83.23M)(65.14M)(70.83M)(84.77M)(85.81M)
Capital Expenditures(67K)(112K)(334K)(264K)(161K)
Acquisitions (Net)00000
Purchases of Investments0(9.63M)000
Sales of Investments009.8M00
Other Investing Activities00000
Investing Cash Flow(67K)(9.74M)9.46M(264K)(161K)
Debt Repayment00074.27M0
Common Stock Issued42.75M39.58M853K191K65.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities92K187K180K77K0
Financing Cash Flow42.84M95.76M1.03M74.54M65.58M
Effect of Forex Changes(130K)(993K)262K(517K)205K
Net Change in Cash(40.59M)19.88M(60.07M)(11.01M)(20.19M)
Free Cash Flow(83.3M)(65.26M)(71.16M)(85.03M)(85.97M)

Immunic, Inc.

NASDAQ:IMUX

Intrinsic Alpha fair value

Locked

Current Price

$7.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.